Baofeng Guo

Dr. Baofeng Guo


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Biochemical Pharmacology
Verified
Journal Article
Closed access
MLMengxin Li
Mengxin Li
XCXuyang Chen
Xuyang Chen
XWXuanzhong Wang
Xuanzhong Wang
XWXiaodong Wei
Xiaodong Wei
DWDing Wang
Ding Wang
LZLing Zhang
Ling Zhang

5 January 2025 in Materials Today Bio
Verified
Journal Article
Open access
QLQian Luo
Qian Luo
JYJiaying Yang
Jiaying Yang
MYMei Yang
Mei Yang
YWYingtong Wang
Yingtong Wang
YLYiran Liu
Yiran Liu
YDYanhong Duo
Yanhong Duo
Central nervous system (CNS) diseases are a major cause of disability and death worldwide. Due to the blood-brain barrier (BBB), drug delivery for CNS diseases is extremely challenging. Nano-delivery systems can overcome the limitations of BBB to deliver drugs to the CNS, improve the ability of drugs to target the brain and provide potential therapeutic methods for CNS diseases. At the same time, the choice of different drug delivery methods (bypassing BBB or crossing BBB) can further optimize the therapeutic effect of the nano-drug delivery system. This article reviews the different methods of nano-delivery systems to overcome the way BBB enters the brain. Different kinds of nanoparticles to overcome BBB were discussed in depth.

1 December 2020 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
QWQian Wang
Qian Wang
SJShengnan Jia
Shengnan Jia
DWDing Wang
Ding Wang
XCXuyang Chen
Xuyang Chen
DKDhan V. Kalvakolanu
Dhan V. Kalvakolanu
LZLing Zhang
Ling Zhang
Glioma stem cells (GSC) are essential for tumor maintenance, invasiveness, and recurrence. Using a global epigenetic screening with an shRNA library, we identified HDAC3 as an essential factor for GSC stemness. Here, we demonstrated that GSCs poorly respond to an HDAC3 inhibitor, RGFP966 (HDAC3i), owing to the production of IL6 and STAT3 activation. To enhance GSC sensitivity to HDAC3i, we explored whether cotreatment with a BRD4 inhibitor, JQ1 (BRD4i), in GSCs produced a better antitumor effect. BRD4i synergistically inhibits GSC growth in association with HDAC3i. HDAC3 inhibition upregulated the acetylation of H3K27, which allowed the recruitment of BRD4 to the GLI1 gene promoter and induced its expression. GLI1, a transcription factor, turned on the expression of IL6, which led to the activation of STAT3 signaling pathways. However, BRD4i inhibited transcription of the GLI1 gene, thereby blocking the GLI1/IL6/STAT3 pathway. In vivo, the HDAC3i/BRD4i combination caused stronger tumor growth suppression than either drug alone. Thus, HDAC3i/BRD4i might provide promising therapies for GBM.

1 August 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
KWKeyan Wang
Keyan Wang
JSJicheng Sun
Jicheng Sun
HZHaoran Zhao
Haoran Zhao
FWFangruyue Wang
Fangruyue Wang
XZXiaoyu Zhang
Xiaoyu Zhang
BGBaofeng Guo
Baofeng Guo
Glioblastoma is the most aggressive and lethal primary brain tumor in adults, with current treatment options offering only limited improvement in patient survival. Despite the advancement of modalities such as immunotherapy, targeted therapy, gene therapy, focused ultrasound, and tumor-treating fields, therapeutic efficacy remains unsatisfactory due to challenges such as the blood-brain barrier, tumor heterogeneity, and treatment resistance. Nanotechnology has emerged as a promising platform to enhance the delivery, specificity, and combinatorial potential of these therapies. By enabling precise and multifunctional delivery of therapeutic agents, nanoscale systems hold the potential to overcome critical biological and pharmacological barriers in glioblastoma treatment. This review provides an overview of recent progress in nanomedicine-based strategies for glioblastoma, critically examines the key challenges that limit their clinical translation, and highlights innovative approaches designed to improve therapeutic outcomes. Future perspectives on how nanotechnology may reshape the landscape of brain tumor treatment are also discussed.

4 March 2022 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
LXLibo Xu
Libo Xu
LZLing Zhang
Ling Zhang
JSJicheng Sun
Jicheng Sun
XHXindan Hu
Xindan Hu
DKDhan V. Kalvakolanu
Dhan V. Kalvakolanu
BGBaofeng Guo
Baofeng Guo
Epigenetic posttranslational modifications are critical for fine-tuning gene expression in various biological processes. SETD8 is so far the only known lysyl methyltransferase in mammalian cells to produce mono-methylation of histone H4 at lysine 20 (H4K20me1), a prerequisite for di- and tri-methylation. Importantly, SETD8 is related to a number of cellular activities, impinging upon tissue development, senescence and tumorigenesis. The double-strand breaks (DSBs) are cytotoxic DNA damages with deleterious consequences, such as genomic instability and cancer origin, if unrepaired. The homology-directed repair and canonical nonhomologous end-joining are two most prominent DSB repair pathways evolved to eliminate such aberrations. Emerging evidence implies that SETD8 and its corresponding H4K20 methylation are relevant to establishment of DSB repair pathway choice. Understanding how SETD8 functions in DSB repair pathway choice will shed light on the molecular basis of SETD8-deficiency related disorders and will be valuable for the development of new treatments. In this review, we discuss the progress made to date in roles for the lysine mono-methyltransferase SETD8 in DNA damage repair and its therapeutic relevance, in particular illuminating its involvement in establishment of DSB repair pathway choice, which is crucial for the timely elimination of DSBs.

8 November 2023 in Phytomedicine
Verified
Journal Article
Closed access
LXLibo Xu
Libo Xu
LZLing Zhang
Ling Zhang
SZShengnan Zhang
Shengnan Zhang
JYJiaying Yang
Jiaying Yang
AZAonan Zhu
Aonan Zhu
BGBaofeng Guo
Baofeng Guo